GlassScriptPhysician profile
Randy S Stoloff
NPI 1417928318
$1,463.74
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $673 · 2021: $572.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $343.48 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $270.11 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $197.12 | 2019-2021 | |
| Genzyme Corporation | $120.86 | 2019-2021 | |
| Novo Nordisk INC | $115.41 | 2021 | |
| Pfizer INC. | $91.12 | 2019-2021 | |
| Optinose US, INC. | $77.71 | 2019-2021 | |
| Genentech USA, INC. | $49.77 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $42.42 | 2021 | |
| Octapharma USA, INC. | $41.72 | 2020 | |
| Amarin Pharma, INC. | $34.42 | 2021 | |
| Alk-Abello, INC | $19.18 | 2020 | |
| Kaleo, INC. | $19.14 | 2021 | |
| Phadia US INC. | $15.80 | 2020 | |
| Shire North American Group INC | $12.94 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $12.54 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Stoloff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.